Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Short-Term Debt : $0.24 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Short-Term Debt?

Clinuvel Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.24 Mil.

Clinuvel Pharmaceuticals's quarterly Short-Term Debt declined from Dec. 2022 ($0.22 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.24 Mil).

Clinuvel Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Short-Term Debt Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															0.19	-	0.22	-	0.24

Clinuvel Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Clinuvel Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.